All In Biotech

Drug Trial Radar · NCT07388511

A Study of Elenestinib in Healthy Adult Female Participants

A Phase 1, Open-Label Study to Evaluate the Effect of Elenestinib on the Pharmacokinetics of Midazolam and Combined Oral Contraceptives, Levonorgestrel/Ethinyl Estradiol, in Healthy Adult Female Participants

Last checked: Nov 20, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Feb 5, 2026

Primary completion

Apr 2, 2026

Study completion Apr 2, 2026

Sponsor

Sponsor type
Industry
First posted
Feb 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main objectives of this study are to determine the effect of elenestinib on the pharmacokinetic parameters (how the drug is absorbed, distributed, and processed by the body) of midazolam, and to determine the effect of elenestinib on the pharmacokinetic parameters of levonorgestrel/ethinyl estradiol, when given as a combined oral contraceptive. Healthy adult participants will receive midazolam and levonorgestrel/ethinyl estradiol with and without elenestinib and have blood samples taken.

Conditions

  • Healthy Participants

Interventions

  • ElenestinibDrug

    Specified dose on specified days

  • MidazolamDrug

    Specified dose on specified days

  • Levonorgestrel/Ethinyl EstradiolDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (AUC0-t)Time frame: Up to 27 days
  2. Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-inf)Time frame: Up to 27 days
  3. Percent of AUC0-inf extrapolated (AUC%extrap)Time frame: Up to 27 days
  4. Maximum observed concentration (Cmax)Time frame: Up to 27 days
  5. Time to reach Cmax (Tmax)Time frame: Up to 27 days
  6. Apparent first-order terminal elimination half-life (t1/2)Time frame: Up to 27 days
  7. Apparent total plasma clearance after oral administration (CL/F)Time frame: Up to 27 days
  8. Apparent volume of distribution during the terminal elimination phase after oral administration (Vz/F)Time frame: Up to 27 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion, Inc

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.